Combined cocaine and HIV vaccine

可卡因和艾滋病毒联合疫苗

• 批准号: 8884699
• 负责人: TIMOTHY J CARDOZO
• 金额: $ 6.53万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-15 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8884699
• 关键词: AIDS/HIV problem; Address; Antibodies; Antibody Formation; Antigens; Award; Biomedical Research; Clinical Trials; Cocaine; Cocaine Users; Crack Cocaine; Data; Drug abuse; Epitopes; Glycoproteins; HIV; HIV Infections; HIV vaccine; Health; Intervention; Laboratories; Molecular; National Institute of Drug Abuse; Population; Recording of previous events; Research; Scaffolding Protein; Scientist; Self Administration; Solid; Substance abuse problem; Surface; Technology; Time; Vaccines; Work; base; design; high risk; inner city; programs; scaffold; substance abuser; transmission process

DESCRIPTION (provided by applicant): Targeting the high-risk groups that are responsible for most of the transmission of HIV is a major challenge in biomedical research on HIV/AIDS. Substance abusers are one of the key high-risk groups, and, specifically, inner city crack cocaine users are three times more likely than non-users to be infected with HIV. We hypothesize that a vaccine that raises protective antibodies simultaneously to both cocaine and HIV could be a high-impact intervention in these populations. Such a vaccine may be feasible, because the first epitopes shown to protect against the acquisition of HIV have been identified by a consortium of scientists analyzing the results of the recent RV144 trial (Haynes et. al. NEJM 2012). Their analysis showed that the protective epitopes are located in the second variable loop (V2 loop) of the surface envelope glycoprotein of the HIV virus. Over the past few years, my laboratory has developed a technology platform for eliciting specific antibody responses from variable loop epitopes, including the V2 loop. Based on these data, we believe that we can develop an immunogen capable of eliciting HIV-protective antibodies. By coincidence, the same scaffold protein used to elicit these antibodies in our work has been used successfully as a cocaine vaccine in a clinical trial. Thus, an advanced starting point is present to develop a combined cocaine and HIV vaccine. Such a vaccine would be a precedent-setting molecular intervention at the intersection of HIV/AIDS and substance abuse, and may have a transformative effect on both fields. In the adaptation of our HIV vaccine immunogen design work to the problem of drug abuse, this proposed project represents a significant departure from the ideas and approaches that are currently being pursued in the our lab, so this proposal is ideal for the NIDA Avante-Garde Award Program for HIV/AIDS Research.

描述（由申请人提供）：针对负责艾滋病毒大部分传播的高风险群体是艾滋病毒/艾滋病生物医学研究的主要挑战。滥用药物是关键的高风险群体之一，具体来说，内城市裂纹可卡因使用者的可能性是非用户感染艾滋病毒的三倍。我们假设一种同时与可卡因和艾滋病毒同时提高保护性抗体的疫苗可能是对这些人群的高度影响干预措施。这样的疫苗可能是可行的，因为已经通过一个科学家的联盟鉴定出证明可以预防艾滋病毒的第一个表位，分析了最近的RV144试验的结果（Haynes等人NEJM 2012）。他们的分析表明，保护性表位位于HIV病毒的表面包膜糖蛋白的第二个变量环（V2环（V2环）中。在过去的几年中，我的实验室开发了一个技术平台，用于从包括V2环在内的可变循环表位中引起特定的抗体响应。基于这些数据，我们认为我们可以开发能够引起HIV保护抗体的免疫原。偶然，在临床试验中，用于引起我们工作中这些抗体的同一支架蛋白已成功用作可卡因疫苗。因此，存在一个先进的起点，以开发可卡因和HIV疫苗。这种疫苗将是在艾滋病毒/艾滋病和药物滥用的交集处进行先例的分子干预，并且可能对这两个领域都有变革性的影响。在适应我们的HIV疫苗免疫原设计工作中，该拟议项目与当前在我们的实验室中正在探讨的思想和方法有很大的不同，因此该提案非常适合NIDA Avante-Garde奖对HIV/AIDS研究的理想选择。